Results 131 to 140 of about 2,330 (177)
Some of the next articles are maybe not open access.
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)
Canadian Journal of Health Technologies, 2022What Is the CADTH Reimbursement Recommendation for Trikafta? CADTH recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years and older who have at least one F508del mutation in the CFTR gene, if certain conditions are met.
openaire +1 more source
Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor
Pediatric Pulmonology, 2023AbstractIntroductionReports of neuropsychiatric symptoms proximal to cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation are emerging, but their prevalence and management remain poorly characterized.MethodsRetrospective chart review was used to categorize symptom trajectories of all adults at a single CF Center who initiated
Evelyne Baroud +2 more
openaire +2 more sources
Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy
Journal of Cystic Fibrosis, 2022Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA, Trikafta) is the newest Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator drug approved by the Food and Drug Administration. Post-marketing reports with earlier CFTR modulators suggest these medications can impact mood, and in clinical trials an adverse effect of headache was reported ...
Suyeon Heo +6 more
openaire +2 more sources
Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis
Pediatric Pulmonology, 2022ETI treatment reduces inflammatory markers and positive bacterial cultures on BAL in PwCF. These findings suggest that ETI has a greater impact on chronic infection and inflammation than ivacaftor alone. However, airway inflammation persists in a fraction of treated individuals, indicating an ongoing need to optimize other treatments in a subset of ...
Richard C. De Vuyst +4 more
openaire +2 more sources
Elexacaftor/tezacaftor/ivacaftor outpatient desensitization
Annals of Allergy, Asthma & Immunology, 2022Ramya Balijepally +4 more
openaire +2 more sources
SAGE Open MedicineObjective: This study aimed to conduct a systematic review and meta-analysis of randomized controlled trials to evaluate the effects of elexacaftor–tezacaftor–ivacaftor (ELX-TEZ-IVA) on patients with cystic fibrosis (CF). Methods: A systematic search was
Rong He, Fei Lin
exaly +2 more sources
Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor
Pediatric PulmonologyABSTRACT Background Due to the dysfunction and destruction of pancreatic cells in individuals with cystic fibrosis (CF), most require lifelong exogenous pancreatic enzyme supplementation. The objective of this study was to determine if elexacaftor/tezacaftor/ivacaftor (ETI) treatment improves ...
Madison Pranske +5 more
openaire +1 more source
Effects of Elexacaftor/Tezacaftor/Ivacaftor on the Sinonasal Airspace in Cystic Fibrosis
The LaryngoscopeABSTRACT Objectives People with Cystic Fibrosis ( CF ) experience significant sinonasal airway opacification, leading to chronic airway‐related conditions. The triple combination therapy Elexacaftor/Tezacaftor/Ivacaftor (
Michelle H. Kim +4 more
openaire +2 more sources
Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)
Canadian Journal of Health TechnologiesReimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Delayed Bullous Drug Eruption Induced by Elexacaftor/Tezacaftor/Ivacaftor
Pediatric DermatologyABSTRACT Elexacaftor/tezacaftor/ivacaftor is a novel “triple therapy” drug which has been shown in clinical trials to reduce morbidity and mortality in cystic fibrosis patients. Few reports of serious cutaneous adverse reactions to elexacaftor/tezacaftor/ivacaftor leading to drug discontinuation have been previously documented, all ...
Tatiana Ninkov +5 more
openaire +2 more sources